Decades of infectious disease expertise
The Microbiotix management team is dedicated to finding innovative solutions to today’s most serious unmet needs in infectious disease.
Donald T. Moir, PhD
Chief Scientific Officer
Dr. Moir’s twenty-five year career has spanned a wide range of molecular biology, encompassing the discovery and validation of antibacterial drug targets, antibacterial drug discovery, bacterial diagnostic marker discovery, human genome physical mapping and cDNA mapping, the discovery of human markers for drug metabolism, and the cloning and expression of heterologous genes in the yeast S. cerevisiae. Previously, Dr. Moir held the positions of Research Director and Scientific Advisor at Genome Therapeutics Corporation. Dr. Moir received a PhD in Biological Chemistry from Harvard University and a B.S. in Chemistry from the University of North Carolina at Chapel Hill. He has authored nearly 50 manuscripts and patent applications.
Terry L. Bowlin, PhD
President & CEO
Dr. Bowlin has had a distinguished career encompassing over thirty years of anti-infective research, development, and management experience with pharmaceutical and biotechnology companies. Dr. Bowlin has extensive experience in drug discovery and development. Previously, Dr. Bowlin held the positions of Vice President, Research, at BioChem Pharma, and Director of Immunology at Marion Merrell Dow. Dr. Bowlin’s postdoctoral research was done at National Institutes of Health, and predoctoral research at the Cleveland Clinic. Dr. Bowlin holds a PhD in Cell Biology/Immunology from Cleveland State University.
Mr. Gauthier is a skilled executive with over thirty years of pharma/biotech/ diagnostic experience with twenty-two years in business/corporate development and management consulting. Mr. Gauthier has a successful track record in developing strategy, structuring, negotiating, closing and managing deals at Diagnocure, Phytobiotech and BioChem Pharma. He has a BS and MBA from McGill University.